By
Eric Volkman
|
More Articles
January 10, 2013
|
An advisory committee of the Food and Drug Administration has recommended approval for Johnson & Johnson's (NYSE: JNJ ) next-generation diabetes treatment canagliflozin, the company announced in a press release. The vote was 10 to 5 in favor of the drug, which, if given final approval, will be sold under the trade name of Invokana.
The medication treats type 2 diabetes in adult patients, and comes in the form of a once-a-day pill. The FDA panel's recommendation comes in spite of concerns about certain cardiovascular risks the drug carries, as well as possible reduced benefits to patients with impaired kidney function.
Canagliflozin was developed by Janssen Research and Development, a unit of Johnson & Johnson.
More Expert Advice from The Motley Fool
In the world of health care, companies simply don't come any bigger than Johnson & Johnson. Many own the stock, but few understand its story. Offering everything from baby powder to biologics, critics think the company has spread itself too thin, becoming nothing more than a bloated corporate whale. Is this true, or is J&J a
well-diversified giant that's perfect for your portfolio? Make sure you understand the full story behind the stock, along with its key opportunities and risks, by checking out our brand new premium report on Johnson & Johnson. To claim your copy simply
click here now for instant access.
RSS Headlines
Fool UK